Ms. Najla Guthrie
Ms. Najla Guthrie, President/CEO is an internationally recognized scientist in the field of nutrition and breast cancer. Her original research, conducted at the Centre for Human Nutrition of the University of Western Ontario, focused on the anti-cancer effects of minor food components, flavonoids, limonoids and tocotrienols, in cell culture, animal models and clinical trials. Ms. Guthrie has published over 32 papers in peer-reviewed journals and has given numerous invited presentations at national and international scientific and industry events. Her research, which has demonstrated the anti-cancer properties of citrus juices and their constituent flavonoids, continues to generate a tremendous amount of scientific and media interest. A founding shareholder, Ms. Guthrie has successfully transitioned from a nutraceutical medicines researcher to CEO of KGK. The Company has under her leadership established, and executed on, a strategic plan to leverage its research infrastructure and generate sufficient capital to finance the development of new and patented nutraceutical product groups of its own. Ms. Guthrie has led and managed the Company's profitable growth of its contract research business over the past 21 years; and has been responsible for recruitment of an integrated research and product development team that today maintains a reputation for world-class nutraceutical science. Ms. Guthrie is responsible for the strategic development of the patenting process, marketing and sales strategies and business development. She is also responsible for the commercialization and licensing of KGK's cholesterol reduction product currently being marketed. In addition, Ms. Guthrie is widely recognized as a leading nutraceutical industry expert and spokesperson; as well as being active in several nutraceutical industry groups.
Malkanthi Evans, D.V.M., M.Sc., Ph.D.
Dr. Mal Evans is the scientific director at KGK Science. She earned her master's and doctorate degrees in physiology from the University of Guelph and received her D.V.M with distinction in physiology from the University of Sri Lanka. Dr. Evans pioneered research in chronobiology and her landmark work in this area was the first of its kind in North America. Her studies in this area support research conducted in the US and Europe on the impact of cellular oscillatory systems on the microbiome, cognition, sleep wake rhythms, shift work, chronic disease etc. and overflow into application in the supplement industry.
Dr. Evans contributes her specialized knowledge to dietary supplement research, study design and protocol development, as well, she authors final reports and manuscripts for publication in peer reviewed journals. She brings her experience and knowledge in Evidence-Based Medicine into Evidence-Based Nutrition. Her expertise encompasses research in numerous areas including gut health and the microbiome, weight management, cardiovascular health, cognition, menopause, hypertension, arthritis, digestive health, eye health, vitamin research, women's and men's health, oxidative stress, immune function, allergies, satiety, dermatology, bioavailability, and various pre-disease and disease indications. Dr. Evans has authored more than 60 peer-reviewed publications and over 100 protocols and clinical study reports for presentation to Health Canada, FDA and/or EFSA for claims substantiation. Dr. Evans is a frequent speaker at conferences on clinical trial design and the need for a new paradigm in study design in identifying biomarkers for the dietary supplement industry. She presents at scientific meetings and contributes to industry publications. Recently, Dr. Evans and her research team, at KGK Science, has developed an Augmented RCT design and global indices that capture the multifaceted nature of dietary supplements, while still keeping within regulatory guidelines for claims.
Stephen Holmes, CPA, CA.
Stephen Holmes, ACA, joined KGK in March of 2018 as Vice President of Finance. Stephen brings significant financial and operational experience to KGK, having held leadership positions at various multinational corporations as well as medium sized enterprises, including the past role of CFO of a publicly traded Canadian company. Stephen earned his Bachelor of Administrative and Commercial Studies at the University of Western Ontario and has been a Chartered Accountant with the Institute of Chartered Accountants in Ireland since 2008.
Ashley ten Haaf, CCRP
Ashley ten Haaf has been the Director of Clinical Operations at KGK Science Inc. since August of 2018.
In one of her prior roles Ashley was the Clinical Project Manager at an innovative biopharmaceutical company. Here she led all clinical and operational aspects for the company’s primary oncology assets; enabling the success and development of the company’s first in human, phase one trials.
Ashley has over 15 years of experience in the clinical trials field, spanning multiple therapeutic areas, in every phase of development. Ashley began her career in Clinical Trials with various positions at London Health Sciences Centre, where she actively participated in the facilitation of over 100 pharmaceutical research trials. After executing in trials as a Clinical Research Manager over 5 years, Ashley moved into trial development assisting investigators to design and execute investigator initiated studies.
Ashley holds a Bachelor’s degree in Science from the University of Waterloo and a Graduate certificate in Clinical Research from Western University. She obtained her CCRP designation in 2012 and most recently Ashley obtained a certificate in Project Management from Western University.